Trials / Completed
CompletedNCT00880841
A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone
A Single-Dose, 1-Period, 1-Treatment Pilot Study of an Investigational Capsule Formulation of 2 mg/.05 mg Buprenorphine/Naloxone Under Fasting Conditions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 6 (actual)
- Sponsor
- NanoSHIFT LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A single-dose pilot study of an investigational capsule formulation of 2 mg/.05 mg Buprenorphine/Naloxone. NIDA Contract No. HHSN271200577414C
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Buprenorphine / Naloxone | oral formulation of buprenorphine / naloxone |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-05-01
- Completion
- 2009-05-01
- First posted
- 2009-04-14
- Last updated
- 2017-06-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00880841. Inclusion in this directory is not an endorsement.